Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 60

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 60
---
 Yona Keisari of Tel Aviv University, Alpha Tau’s Chief Physics Officer and Chief Scientific Officer,
respectively. Together, they founded our company with the goal of bringing this innovative technology out of the laboratory and into patients,
in order to bring hope to cancer patients around the world.

The address of our principal
executive offices is Kiryat HaMada St. 5, Jerusalem, Israel 9777605 and its telephone number is +972 (3) 577-4115. Our agent for
service of process in the United States is Alpha Tau Medical, Inc., 1 Union Street 3rd Floor, Lawrence, MA 01840.

<div align='center'>3

RISK FACTORS</div>

An investment in our securities
involves a high degree of risk. Our business, financial condition or results of operations could be adversely affected by any of these
risks. You should carefully consider the risk factors discussed under the caption “Item 3: Key Information -Risk Factors”
in our Annual Report on Form 20-F for the year ended December 31, 2022, and in any other filing we make with the SEC subsequent to the
date of this prospectus, each of which are incorporated herein by reference, and in any supplement to this prospectus, before making your
investment decision. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not
presently known to us or that we currently deem immaterial may also affect our operations. Past financial performance may not be a reliable
indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of
these risks actually occurs, our business, business prospects, financial condition or results of operations could be seriously harmed.
This could cause the trading price of our ordinary shares to decline, resulting in a loss of all or part of your investment. Please also
read carefully the section below entitled “Cautionary Note Regarding Forward-Looking Statements.”

<div align='center'>OFFER STATISTICS AND EXPECTED TIMETABLE</div>

We may sell from time to time
pursuant to this prospectus (as may be detailed in a prospectus supplement) an indeterminate number of ordinary shares, warrants to purchase
ordinary shares, debt securities, subscription rights and/or units comprised of any of the foregoing securities as shall have a maximum
aggregate offering price of $200,000,000. The actual price per share or per